Consequently, whether erlotinib is superior to gefitinib in the treatment of young patients with brain metastases following EGFR-mutant lung adenocarcinoma, a prospective randomized controlled study of larger samples is required for clarification. The gene discussed is EGFR; the disease is lung adenocarcinoma.